Varlirix (GlaxoSmithKline).
GlaxoSmithKline (formerly SmithKline Beecham) has developed and launched Varilrix, a preparation of live, attenuated Oka-strain varicella zoster virus, for immunization against varicella zoster infections [455138]. By the end of 1998, Varilrix was available in a few European countries and in India [284490], [455138]. By 2001, the vaccine was also available in Brazil and Hong Kong [396267].
Arvin
Ann M
AM
Stanford University, CA 94305-5208, USA. AArvin@Stanford.edu
D000818:Animals; D019433:Chickenpox Vaccine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods; D014645:Herpesvirus 3, Human / Q000187:drug effects / Q000276:immunology; D006801:Humans
D019433:Chickenpox Vaccine